Sutro Biopharma, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a STRO research report →
Range $43 – $60
Price Chart
About the company
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders.
- CEO
- Jane Chung
- IPO
- 2018
- Employees
- 133
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on STRO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $204.77M
- P/E
- -1.21
- PEG
- -0.04
- P/S
- 4.48
- P/B
- -3.39
- EV/EBITDA
- -1.20
- Div Yield
- 0.00%
- Gross Margin
- 97.20%
- Op Margin
- -309.87%
- Net Margin
- -395.25%
- ROE
- 185.30%
- ROIC
- -95.49%
Latest fiscal year · YoY change
- Revenue
- $102.48M+65.2%
- Gross Profit
- $95.16M+73.6%
- Op Income
- $-104,952,000
- Net Income
- $-191,086,000+16.0%
- EPS
- $-22.49+24.0%
- OCF Growth
- +7.5%
- FCF Growth
- +8.1%
- 52W High
- $43.85
- 52W Low
- $7.15
- 50D MA
- $26.48
- 200D MA
- $21.56
- Beta
- 1.51
- RSI (14)
- 38
- Avg Volume
- 364.56K
No earnings-call transcripts are available for STRO yet.
- Free Float
- 70.6%
- Shares Outstanding
- 9.68M
- Float Shares
- 6.83M
of shares held by institutions
61 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 375.79K | ▼ 3.31M |
| Point72 Asia (Singapore) Pte. Ltd. | 31.03K | ▼ 30.04K |
| Two Sigma Advisers, LP | 17.58K | ▼ 221.82K |
| Cwm, LLC | 983 | ▼ 516 |
| Cubist Systematic Strategies, LLC | 10 | ▼ 6.07K |
| Accredited Wealth Management, LLC | 5 | ▼ 995 |
| Comerica Bank | 3 | ▼ 46 |
Held by 128 ETFs
Biggest fund positions in STRO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 26 | Wigginton Jon Marc | other | 10,000 |
| Jun 5, 26 | Petree Daniel H | other | 10,000 |
| Jun 5, 26 | PANEK JAMES P | other | 10,000 |
| Jun 5, 26 | Lobacki Joseph M | other | 10,000 |
| Jun 5, 26 | Jagpal Sukhi | other | 10,000 |
| Jun 5, 26 | Hunter Heidi | other | 10,000 |
| Jun 5, 26 | Dybbs Michael | other | 10,000 |
| Jun 5, 26 | MATSUI CONNIE | other | 10,000 |
| Jun 2, 26 | Chow Gregory K. | other | 2,500 |
| Jun 2, 26 | Chow Gregory K. | other | 2,500 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our STRO coverage
Recent articles, reports, and earnings notes.
No research on STRO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate STRO report →Why is Sutro Biopharma Stock Falling On Wednesday?
benzinga.com · Aug 12
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
globenewswire.com · Aug 12
Here Are Friday’s Top Wall Street Analyst Research Calls: Baker Hughes, Etsy, HubSpot, Instacart, JetBlue, Roku, SpaceX, Tower Semiconductor, Trade Desk, and More
247wallst.com · Aug 7
Affinity Asset Advisors LLC Grows Stock Holdings in Sutro Biopharma, Inc. $STRO
defenseworld.net · Jul 25
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
globenewswire.com · May 14
Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More
247wallst.com · Apr 30
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
globenewswire.com · Apr 19
Sutro Biopharma (NASDAQ:STRO) Trading 10.4% Higher on Analyst Upgrade
defenseworld.net · Apr 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.